Bell Investment Advisors Inc Purchases 14 Shares of Eli Lilly and Company (NYSE:LLY)

Bell Investment Advisors Inc raised its position in Eli Lilly and Company (NYSE:LLY) by 4.5% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 322 shares of the company’s stock after acquiring an additional 14 shares during the quarter. Bell Investment Advisors Inc’s holdings in Eli Lilly and Company were worth $292,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Barings LLC bought a new position in shares of Eli Lilly and Company in the second quarter worth about $436,000. Achmea Investment Management B.V. raised its stake in shares of Eli Lilly and Company by 0.6% in the second quarter. Achmea Investment Management B.V. now owns 60,735 shares of the company’s stock worth $54,988,000 after buying an additional 364 shares during the period. Y.D. More Investments Ltd bought a new position in shares of Eli Lilly and Company in the second quarter worth about $112,000. Jupiter Asset Management Ltd. raised its stake in shares of Eli Lilly and Company by 2.0% in the second quarter. Jupiter Asset Management Ltd. now owns 20,819 shares of the company’s stock worth $18,849,000 after buying an additional 407 shares during the period. Finally, American Century Companies Inc. raised its stake in Eli Lilly and Company by 5.1% during the 2nd quarter. American Century Companies Inc. now owns 2,069,881 shares of the company’s stock valued at $1,874,029,000 after purchasing an additional 100,426 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $920.89 on Thursday. Eli Lilly and Company has a twelve month low of $516.57 and a twelve month high of $972.53. The stock has a market capitalization of $875.22 billion, a price-to-earnings ratio of 135.62, a P/E/G ratio of 2.73 and a beta of 0.42. The stock has a fifty day simple moving average of $896.20 and a two-hundred day simple moving average of $831.11. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. On average, analysts predict that Eli Lilly and Company will post 16.51 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Thursday, August 15th were paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.56%. The ex-dividend date of this dividend was Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 1,441 shares of the company’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $915.02, for a total transaction of $1,318,543.82. Following the completion of the sale, the insider now directly owns 97,367,369 shares in the company, valued at approximately $89,093,089,982.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 661,900 shares of company stock worth $604,721,602 in the last three months. 0.13% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Berenberg Bank lifted their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Deutsche Bank Aktiengesellschaft raised Eli Lilly and Company from a “hold” rating to a “buy” rating and lifted their target price for the company from $725.00 to $1,025.00 in a research note on Monday, August 12th. JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $900.00 to $1,000.00 and gave the company an “overweight” rating in a report on Thursday, July 11th. Guggenheim raised their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a report on Friday, August 16th. Finally, Wells Fargo & Company raised their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a report on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $961.76.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.